Lenvatinib Mesylate Intermediate CAS 205448-65-3 Purity > 98.0% (HPLC) Hoobkas
Ruifu Chemical Supply Lenvatinib Mesylate Intermediates Nrog Siab Purity
Lenvatinib Mesylate CAS 857890-39-2
4-Chloro-7-Methoxyquinoline-6-Carboxamide CAS 417721-36-9
Desquinolinyl Lenvatinib;1-(2-Chloro-4-Hydroxyphenyl)-3-Cyclopropylurea CAS 796848-79-8
Tom ntej: Methyl 7-Methoxy-4-Oxo-1,4-Dihydroquinoline-6-Carboxylate CAS 205448-65-3
Tom ntej: Methyl 4-Amino-2-Methoxybenzoate CAS 27492-84-8
5-(Methoxymethylene)-2,2-Dimethyl-1,3-Dioxane-4,6-Dione CAS 15568-85-1
4-Amino-3-Chlorophenol CAS 17609-80-2
4-Amino-3-Chlorophenol Hydrochloride CAS 52671-64-4
Tom ntej: Methyl 4-Chloro-7-Methoxyquinoline-6-Carboxylate CAS 205448-66-4
Tshuaj npe | Tom ntej: Methyl 7-Methoxy-4-Oxo-1,4-Dihydroquinoline-6-Carboxylate |
Synonyms | 1,4-Dihydro-7-Methoxy-4-Oxo-6-Quinolinecarboxylic Acid Methyl Ester;7-Methoxy-4-Oxo-1,4-Dihydro-Quinoline-6-Carboxylic Acid Methyl Ester;Lenvatinib Intermediate 3 |
CAS Nr | 205448-65-3 |
CAT Number | RF-PI 1973 |
Tshuag xwm txheej | Hauv Tshuag, Muaj Peev Xwm Ntau Lawm 50 MT / Xyoo |
Molecular Formula | C12H11NO4 |
Molecular Luj | 233.22 Nws |
Boiling Point | 421.0 ± 45.0 ℃ |
Qhov ntom | 1.267 ± 0.060g / cm3 |
Hom | Ruifu Tshuaj |
Yam khoom | Specifications |
Qhov tshwm sim | Off-White to Yellowish Powder |
Purity / Analysis Method | > 98.0% (HPLC) |
Poob rau ziab | <1.00% |
Residue ntawm Ignition | <0.50% |
Tag nrho cov impurities | <2.00% |
H-NMR | Raws li tus qauv |
Test Standard | Enterprise Standard |
Kev siv | Pharmaceutical Intermediates |
Pob: Lub raj mis, Aluminium ntawv ci hnab, 25kg / Cardboard Nruas, los yog raws li tus neeg yuav tsum tau muaj
Cia txias:Khaws rau hauv cov thawv ntim khoom ntawm qhov chaw txias thiab qhuav;Tiv thaiv los ntawm lub teeb thiab noo noo
Methyl 7-Methoxy-4-Oxo-1,4-Dihydroquinoline-6-Carboxylate (CAS: 205448-65-3) yog ib qho nruab nrab ntawm Lenvatinib Mesylate (CAS: 857890-39-2).Lenvatinib, muag raws li lub npe Lenvima ntawm lwm tus, yog cov tshuaj tiv thaiv kab mob qog noj ntshav rau kev kho mob ntawm qee yam qog nqaij hlav qog noj ntshav thiab rau lwm yam mob qog noj ntshav.Nws tau tsim los ntawm Eisai Co. thiab ua raws li ntau yam kinase inhibitor tiv thaiv VEGFR1, VEGFR2 thiab VEGFR3 kinases.Lenvatinib tau txais kev pom zoo (txij li xyoo 2015) rau kev kho mob qog noj ntshav sib txawv uas yog nyob hauv zos rov tshwm sim lossis metastatic, kev loj hlob, thiab tsis teb rau kev kho mob nrog cov xov tooj cua iodine (radioiodine).Thaum lub Tsib Hlis 2016, US Food and Drug Administration (FDA) tau pom zoo nws (ua ke nrog everolimus) rau kev kho mob ntawm lub raum cell carcinoma tom qab ib qho kev kho mob angiogenic ua ntej.Cov tshuaj kuj tau pom zoo nyob rau hauv Teb Chaws Asmeskas thiab European Union rau hepatocellular carcinoma uas tsis tuaj yeem tshem tawm kev phais hauv cov neeg mob uas tsis tau txais kev kho mob qog noj ntshav los ntawm qhov ncauj lossis txhaj tshuaj.